285 related articles for article (PubMed ID: 31810502)
21. Nucleotide analogs related to acyclovir and ganciclovir are effective against murine cytomegalovirus infections in BALB/c and severe combined immunodeficient mice.
Smee DF; Sugiyama ST; Reist EJ
Antimicrob Agents Chemother; 1994 Sep; 38(9):2165-8. PubMed ID: 7811037
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of ganciclovir and cidofovir against human cytomegalovirus replication in SCID mice implanted with human retinal tissue.
Bidanset DJ; Rybak RJ; Hartline CB; Kern ER
Antiviral Res; 2004 Jul; 63(1):61-4. PubMed ID: 15196821
[TBL] [Abstract][Full Text] [Related]
23. Questioning the Extreme Neurovirulence of Monkey B Virus
Eberle R; Jones-Engel L
Adv Virol; 2018; 2018():5248420. PubMed ID: 29666644
[TBL] [Abstract][Full Text] [Related]
24. Prolonged and potent therapeutic and prophylactic effects of (S)-1-[(3-hydroxy-2-phosphonylmethoxy)propyl]cytosine against herpes simplex virus type 2 infections in mice.
Yang H; Datema R
Antimicrob Agents Chemother; 1991 Aug; 35(8):1596-600. PubMed ID: 1929331
[TBL] [Abstract][Full Text] [Related]
25. Recommendations for prevention of and therapy for exposure to B virus (cercopithecine herpesvirus 1).
Cohen JI; Davenport DS; Stewart JA; Deitchman S; Hilliard JK; Chapman LE;
Clin Infect Dis; 2002 Nov; 35(10):1191-203. PubMed ID: 12410479
[TBL] [Abstract][Full Text] [Related]
26. Combination of antiviral immunotoxin and ganciclovir or cidofovir for the treatment of murine cytomegalovirus infections.
Smee DF; Sidwell RW; Barnett BB
Antiviral Res; 1996 Nov; 32(3):165-71. PubMed ID: 8955511
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological characterization of monkey B virus (Cercopithecine herpesvirus 1) infection in mice.
Ritchey JW; Payton ME; Eberle R
J Comp Pathol; 2005; 132(2-3):202-17. PubMed ID: 15737347
[TBL] [Abstract][Full Text] [Related]
28. Case Report: Late Reactivation of Herpes B Virus After a Monkey Bite: A Case of Severe Meningoencephalitis.
Ponzetto E; Delhez Q; Hoppenbrouwers M; De Schryver N; Serck N; Dugernier T; Duray MC; Gressens B; Vinetti M; Sips GJ; van Kampen J; GeurtsvanKessel CH; van Boheemen S
Am J Trop Med Hyg; 2023 Dec; 109(6):1277-1281. PubMed ID: 37972322
[TBL] [Abstract][Full Text] [Related]
29. Antiviral activities of nucleosides and nucleotides against wild-type and drug-resistant strains of murine cytomegalovirus.
Smee DF; Barnett BB; Sidwell RW; Reist EJ; Holy A
Antiviral Res; 1995 Jan; 26(1):1-9. PubMed ID: 7741517
[TBL] [Abstract][Full Text] [Related]
30. Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects.
Zabawski EJ; Cockerell CJ
J Am Acad Dermatol; 1998 Nov; 39(5 Pt 1):741-5. PubMed ID: 9810890
[TBL] [Abstract][Full Text] [Related]
31. Influence of the treatment protocol upon the in vivo efficacy of cidofovir (HPMPC) and of acyclovir (ACV) formulations in topical treatment of cutaneous HSV-1 infection in hairless mice.
Afouna MI; Mehta SC; Ghanem AH; Higuchi WI; Kern ER; DeClercq E; El-Shattawy HH
J Pharm Sci; 1999 May; 88(5):530-4. PubMed ID: 10229644
[TBL] [Abstract][Full Text] [Related]
32. Decision Tool for Herpes B Virus Antiviral Prophylaxis after Macaque-Related Injuries in Research Laboratory Workers.
Barkati S; Taher HB; Beauchamp E; Yansouni CP; Ward BJ; Libman MD
Emerg Infect Dis; 2019 Sep; 25(9):. PubMed ID: 31441751
[TBL] [Abstract][Full Text] [Related]
33. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus.
Medveczky MM; Horvath E; Lund T; Medveczky PG
AIDS; 1997 Sep; 11(11):1327-32. PubMed ID: 9302441
[TBL] [Abstract][Full Text] [Related]
34. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro.
Williams-Aziz SL; Hartline CB; Harden EA; Daily SL; Prichard MN; Kushner NL; Beadle JR; Wan WB; Hostetler KY; Kern ER
Antimicrob Agents Chemother; 2005 Sep; 49(9):3724-33. PubMed ID: 16127046
[TBL] [Abstract][Full Text] [Related]
35. Synergy of bovine lactoferrin with the anti-cytomegalovirus drug cidofovir in vitro.
van der Strate BW; De Boer FM; Bakker HI; Meijer DK; Molema G; Harmsen MC
Antiviral Res; 2003 Apr; 58(2):159-65. PubMed ID: 12742576
[TBL] [Abstract][Full Text] [Related]
36. Characterization of a spontaneous drug-resistant mutant of monkey B virus (Macacine herpesvirus 1).
Black DH; Maxwell LK; Eberle R
Arch Virol; 2009; 154(9):1495-7. PubMed ID: 19609635
[TBL] [Abstract][Full Text] [Related]
37. Antiviral activity of 9-[[(ethoxyhydroxyphosphinyl)-methoxy]methoxy] guanine against cytomegalovirus and herpes simplex virus.
Kim HT; Kim DK; Kim YW; Kim KH; Sugiyama Y; Kikuchi M
Antiviral Res; 1995 Nov; 28(3):243-51. PubMed ID: 8629816
[TBL] [Abstract][Full Text] [Related]
38. Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance against both ganciclovir and cidofovir.
Harada K; Eizuru Y; Isashiki Y; Ihara S; Minamishima Y
Arch Virol; 1997; 142(2):215-25. PubMed ID: 9125039
[TBL] [Abstract][Full Text] [Related]
39. Effect of Azone upon the in vivo antiviral efficacy of cidofovir or acyclovir topical formulations in treatment/prevention of cutaneous HSV-1 infections and its correlation with skin target site free drug concentration in hairless mice.
Afouna MI; Fincher TK; Zaghloul AA; Reddy IK
Int J Pharm; 2003 Mar; 253(1-2):159-68. PubMed ID: 12593946
[TBL] [Abstract][Full Text] [Related]
40. Cytomegalovirus mutants resistant to ganciclovir and cidofovir differ in susceptibilities to synguanol and its 6-ether and 6-thioether derivatives.
Chou S; Komazin-Meredith G; Williams JD; Bowlin TL
Antimicrob Agents Chemother; 2014; 58(3):1809-12. PubMed ID: 24379208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
